Highlights

  • Cochlear (ASX:COH) recorded FY26 sales revenue of AUD 2.34bn, down 1% on a reported basis.
  • FY26 underlying net profit declined 22% to AUD 322.4mn from AUD 414.5mn.
  • Cochlear implant units increased 5% to 56,692 during FY26.
  • At its October 2026 AGM, the company reaffirmed FY27 underlying net profit guidance of AUD 330mn–350mn.

Cochlear Limited develops and supplies implantable hearing solutions, including cochlear implants, sound processors and bone-conduction systems, for children and adults across international markets. At its annual general meeting on 26 October 2026, the company reaffirmed its FY27 underlying net profit guidance and discussed commercial uptake of its Nucleus Nexa platform. During trading on 26 October 2026, Cochlear (ASX:COH) was quoted at AUD 142.65, down 2.83% for the session at the quoted point. The update follows FY26 results showing lower underlying earnings despite increased implant unit volumes.

Company Business

Cochlear (ASX:COH) operates through three principal revenue categories: cochlear implants, services and acoustics. Implant systems include surgically implanted devices and external sound processors designed for people with severe to profound hearing loss. Services revenue includes replacement processors, upgrades, accessories and related offerings for existing recipients. Its acoustics business supplies bone-conduction hearing solutions.

The company manufactures, develops and supports hearing technology across the Americas, Europe, the Middle East, Africa and Asia Pacific. Clinical practices, reimbursement arrangements, referral pathways and surgical capacity vary across these regions. Cochlear also invests in research, software, connectivity and new implant systems intended to support clinical use and ongoing recipient care.

Recent Development

At its October 2026 AGM, Cochlear (ASX:COH) reiterated plans to expand adult cochlear implantation by improving diagnosis, referral and access to surgery. Management said clinical practice guidelines were being implemented across 25 countries, alongside efforts to strengthen professional referral pathways in the US, Germany, the UK and Australia. The initiatives address differences in how adults move from hearing assessment to treatment.

The company also discussed the Nucleus Nexa System, introduced during FY26. By June 2026, the Nexa implant accounted for more than 95% of developed-market cochlear implant sales, with an average price increase of about 3%. Management reported completion of pivotal studies involving its drug-eluting electrode, with results under analysis, and completion of recruitment for pivotal studies of a totally implantable cochlear implant. These programs remain subject to clinical evaluation and relevant regulatory processes.

Cochlear (ASX:COH) also disclosed board renewal arrangements, including the planned appointment of Professor Ian Meredith as a non-executive director from December 2026. The company continues to review its operating cost base while directing spending toward product development and market access.

Financial Performance and Sector Context

For FY26, Cochlear (ASX:COH) reported sales revenue of AUD 2.343bn against AUD 2.356bn in FY25, a 1% reported decline and a 2% increase in constant currency. Underlying net profit was AUD 322.4mn, down 22% from AUD 414.5mn. Gross margin fell to 71% from 74%, while operating expenses increased 5% to AUD 1.251bn. These movements reflected product mix, operating costs, foreign exchange and investment in growth initiatives.

Cochlear implant revenue was AUD 1.435bn, declining 2% on a reported basis but remaining flat in constant currency. Implant units increased to 56,692 from 53,968, reflecting a greater proportion of lower-priced emerging-market devices. Services revenue rose 4% to AUD 634.9mn, while acoustics revenue fell 1% to AUD 273.3mn. The different movements in volumes, sales mix and revenue illustrate why implant shipments alone do not determine overall earnings.

Developed-market demand was affected by insurance approval delays, hospital capacity and elective surgery constraints, while reimbursement settings and geopolitical disruptions influenced particular regions. The company expects low single-digit constant-currency sales revenue growth in FY27 and underlying net profit between AUD 330mn and AUD 350mn.

Risks to Consider

Cochlear (ASX:COH) remains exposed to healthcare reimbursement policies, surgical capacity, regulatory approvals and competition within hearing devices. Delays in referrals or insurance authorisations can extend the period between diagnosis and implantation. Foreign exchange movements affect reported revenue and earnings, while new technology programs require manufacturing investment, clinical evidence and regulatory clearance. The FY26 gross-margin decline and increased operating expenditure also place emphasis on cost execution and product mix.

What to Watch Next

For Cochlear (ASX:COH), the next measurable developments include FY27 cochlear implant volumes, revenue trends in developed markets, Nexa rollout beyond initial markets and changes in service revenue. Further updates on the drug-eluting electrode and totally implantable system will clarify clinical and regulatory progress. Financial disclosures will show whether operating efficiencies and spending decisions are consistent with management’s AUD 330mn–350mn underlying net profit guidance.

Key Insights

Cochlear’s FY26 results combined higher implant volumes with lower reported revenue, gross margin and underlying net profit. The October AGM focused on adult referral initiatives, adoption of Nucleus Nexa and development-stage technologies. FY27 guidance provides a reference point for assessing revenue mix, operating costs and implementation of the company’s strategic programs.